GSK agreed to acquire Rapt Therapeutics for $2.2 billion, taking ownership of ozureprubart, a long‑acting anti‑IgE monoclonal antibody in Phase IIb for food-allergy prophylaxis. The deal consolidates GSK’s allergy portfolio and aims to compete with Novartis/Roche’s Xolair by offering less frequent dosing and broader patient eligibility. GSK said ozureprubart could extend protection with dosing every 8–12 weeks and serve patients ineligible for current anti‑IgE therapy. The transaction gives GSK global rights outside China and accelerates the company’s push into immunology and allergy care ahead of pivotal Phase III plans slated after 2027 data readouts.